Catalyst Wire Dossier Catalyst Wire Dossier

QPI-1007

p53-targeted siRNA · Quark Pharmaceuticals
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for QPI-1007, covering 2013-05-13 to 2020-07-20. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) [Phase 2, Phase 3]

See pricing